Pointe Biotech (Nanjing) Co., Ltd. (hereinafter referred to as: Pointe) and its shareholders formally reached a strategic consensus and completed the signing of the contract

The company raised its earnings forecast for 2022 on estimates of $7.8 billion in annual sales related to COVID-19 testing.

Roche’s third-quarter results have revealed a clear sign that the bumper sales boosting companies that have provided products to diagnose, treat or prevent COVID-19 since the start of the pandemic are starting to tail off.

Becton Dickinson announced on Tuesday a collaboration with Magnolia Medical Technologies, under which the firms will co-sell and comarket the Magnolia Medical Steripath and Steripath Micro Initial Specimen Diversion Device, which complement the BD Vacutainer specimen collection portfolio.

Illumina said on Tuesday that it has partnered with French company GenoScreen on genomic testing for multidrug-resistant tuberculosis.

On October 15, the General Office of Hangzhou Municipal People's Government issued the "Notice on Several Measures to Accelerate the High-Quality Development of Biomedical Industry"

Biodesix said Monday that it has been awarded a US Federal Supply Schedule contract for cancer testing of covered patients served by the Veterans Health Administration and Military Health System.

PBD Biotech said Monday it gained investment funding of ￡2.4 million ($2.7 million) to support clinical trials for its Actiphage rapid screening test for latent tuberculosis infections and their potential to develop into serious disease.

Since October, companies in the pharmaceutical field have successively announced monthly forecasts for the first three quarters.

Canadian diagnostics firm MedMira said on Friday that its Vyra COVID-19 Antigen Test has been CE marked and is now available in countries that accept the designation.

National Health Service England on Wednesday published a five-year strategy on accelerating the adoption of genomics into the British healthcare system. The new strategy places genomics at the heart of a new effort to deliver a sustainable model of healthcare for patients.

On October 13, 2022, the Shenzhen Stock Exchange disclosed that the 73rd Review Meeting of the GEM Listing Committee in 2022 was held and approved Jiaxing Quaero Life Science Co., Ltd. to be listed on the Sci-Tech Innovation Board.

Standard BioTools — formerly Fluidigm — said on Thursday that its Biomark and Juno molecular diagnostic systems have received approval from China's National Medical Products Administration.

GE published a regulatory filing about the spinoff of its healthcare unit, which it expects to complete in the first week of 2023, if the transaction is approved by its board of directors. GE HealthCare will be listed on the Nasdaq under the ticker “GEHC.”

QuidelOrtho on Wednesday reported preliminary third quarter revenues of between $782 million and $785 million.